CD274 and neoplasm: It was approved in 2016 for the treatment of advanced or metastatic urothelial carcinoma [40], since then indications widened and now include advanced melanoma, NSCLC (if PD-L1 expression is over 50% of tumor cells or over 10% of tumor-infiltrating immune cells), TNBC (if tumor-infiltrating immune cells ≥ 1%), renal cell carcinoma, HNSCC, colorectal carcinoma, hepatocellular carcinoma, and gastric carcinoma [5].